Citigroup and UBS are to postpone the initial public offering of Russian pharmaceutical company Pharmstandard, despite success with Russian steelmaker Severstal's $1.1bn (€859.8m) float.

Joint bookrunners Citigroup and UBS pulled the float yesterday because Pharmstandard had to reassess its financial report before floating, according to Kommersant, the Russian business daily.